Metal complexes are extensively used for cancer therapy. The multiple variables available
for tuning (metal, ligand, and metal–ligand interaction) offer unique opportunities for drug …

Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

The platinum-based drugs cisplatin, carboplatin and oxaliplatin are regularly prescribed in
the treatment of cancer and while they are effective, their use is limited by their severe, dose …

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common dose‐limiting side effect
experienced by patients receiving treatment for cancer. Approximately 30 to 40% of patients …

This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …

Chemotherapy induced peripheral neuropathy (CIPN) is a potentially dose limiting side
effect of commonly used chemotherapeutic agents like taxanes, vinca-alkaloids, platinum …

As there are increasing numbers of cancer survivors, more attention is being paid to the long
term unwanted effects patients may experience as a result of their treatment and the impact …

The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …

Pain is a common problem in cancer survivors, especially in the first few years after
treatment. In the longer term, approximately 5% to 10% of survivors have chronic severe …